Praziquantel and artesunate vs praziquantel
Adverse events · people with urinary schistosomiasis
1 finding from 1 review
- no estimate extracted1 study · 156 participantsVery low
Findings
What do systematic reviews say?
62 questions · 66 findings · 7 reviews
No studies found 3 · 4.5%GRADE not reported 3 · 4.5%Very low 8 · 12.1%Low 32 · 48.5%Moderate 14 · 21.2%High 6 · 9.1%
Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) vs praziquantel
Parasitological failure at 1 month · People with S. mansoni infection
It is very uncertain whether artesunate (12 mg/kg) plus praziquantel (40 mg/kg) changes parasitological failure at 1 month compared with praziquantel (40 mg/kg) alone (very low certainty).
1 finding from 1 review
- RR 0.62 [0.35, 1.09]1 study · 75 participantsVery low
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure day 28 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 15.48 [0.9, 267.27]1 study · 187 participantsLow
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.84 [0.95, 3.56]2 studies · 1258 participantsModerate
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.56 [0.88, 2.79]1 study · 1063 participantsModerate
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Early treatment failure · children and adults
Atovaquone‐proguanil showed no clear difference in early treatment failure compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 5.11 [0.25, 104.94]2 studies · 395 participantsLow
Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)
Total failure: day 28 (PCR‐adjusted) · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 3.19 [0.67, 15.22]1 study · 132 participantsLow
Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)
Total failure day 28 PCR‐unadjusted · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.2 [0.49, 2.91]1 study · 132 participantsLow
Atovaquone‐proguanil vs artesunate‐amodiaquine (AS‐AQ)
Early treatment failure · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in early treatment failure compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 13.8 [0.79, 240.11]1 study · 132 participantsLow
Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 1.15 [0.57, 2.34]2 studies · 1168 participantsHigh
Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 0.8 [0.5, 1.3]1 study · 1063 participantsLow
Atovaquone‐proguanil vs artesunate‐atovaquone‐proguanil
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
- Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes onlyRR 5.143 [0.61, 43.52]2 studies · 375 participantsLow
Intervention not reported
Death · Children with severe malaria
The intervention leads to lower death (high certainty).
1 finding from 1 review
- RR 0.76 [0.65, 0.9]4 studies · 5765 participantsHigh
Intervention not reported
Hypoglycaemia episodes · Adults with severe malaria
The intervention leads to lower hypoglycaemia episodes (high certainty).
1 finding from 1 review
- RR 0.36 [0.19, 0.68]2 studies · 1372 participantsHigh
Intervention not reported
Neurological sequelae at day 28 · Children with severe malaria
The intervention showed no clear difference in neurological sequelae at day 28 (moderate certainty).
1 finding from 1 review
- RR 1.23 [0.74, 2.03]1 study · 4857 participantsModerate
Intervention not reported
Neurological sequelae at discharge · Children with severe malaria
The intervention probably leads to higher neurological sequelae at discharge (moderate certainty).
1 finding from 1 review
- RR 1.36 [1.01, 1.83]3 studies · 5163 participantsModerate
Intervention not reported
Time to hospital discharge (days) · Children with severe malaria
1 finding from 1 review
- no estimate extracted3 studies · 113 participantsModerate
Intervention not reported
Hypoglycaemia episodes · Children with severe malaria
The intervention leads to lower hypoglycaemia episodes (high certainty).
1 finding from 1 review
- RR 0.62 [0.45, 0.87]4 studies · 5765 participantsHigh
Intervention not reported
Death · Adults with severe malaria
The intervention leads to lower death (high certainty).
1 finding from 1 review
- RR 0.61 [0.5, 0.75]5 studies · 1664 participantsHigh
Intervention not reported
Neurological sequelae at day 28 · Adults with severe malaria
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found